‘The Global Neuromodulation Devices Market Will be Worth $11.61bn by 2021′ Says Visiongain

By Visiongain, PRNE
Thursday, October 6, 2011

LONDON, October 7, 2011 -


A new report by visiongain, a London-based business information provider, predicts that the global neuromodulation devices market will be worth $11.61bn by 2021. The market generated sales of $2.70bn in 2010, according to Neuromodulation Devices: World Market Prospects 2011-2021,published in October 2011.

Neuromodulation is a rapidly evolving medical technique that provides symptomatic relief either through targeted drug delivery or electrical stimulation. Small electrical devices or drug pumps are surgically implanted. Electrical signals are generated by a pulse generator and sent through electrode wires to either provoke a biological response or release a small dose of a therapeutic agent. The technique has been approved for use in some movement disorders, psychiatric disorders and chronic pain, and is currently undergoing investigation for use in other indications, such as obesity, migraine and heart failure. The neuromodulation devices market is a small, emerging market at present, but one of the fastest growing segments in the medical devices market.

Hemant Mistry, healthcare industry analyst, says: “The market for neuromodulation devices will see strong growth in coming years, driven by a rise in age-related diseases, approval of innovative devices, and increased patient adoption of existing and newly-marketed products. The concept of neuromodulation as a therapeutic option for patients is not new, but has only started to garner interest, owing to patient’s increased dissatisfaction with pharmacological intervention (high level of side effects, intolerance)”.

Visiongain’s research suggests that the world neuromodulation devices market will benefit from extensive research into the mechanisms behind the technology. An understanding of the mechanism by which neuromodulation therapies exert their effect will lead to the development of more effective and innovative devices.  Additionally, there is an imperative need for the medical device companies to increase awareness amongst the patients about neuromodulation devices; this will lead to an increased patient adoption. Furthermore, improvements within the FDA (Food and Drug Administration) to make the device approval process clearer and more efficient will see more innovative devices being granted market approval.

Visiongain predicts that this market will grow rapidly to 2021. The future of the neuromodulation market appears promising and has significant potential for growth and investment, with the increasing demand for safer, less invasive therapies. This new report adds to visiongain’s wide range of analytical reports in healthcare and other industry areas.

To view sample pages please click on:


Web: www.visiongain.com

Table of Contents
1. Executive Summary
1.1 Sector Highlights
1.2 Aims, Scope and Format of the Report
1.2.1 Chapter Outline
1.3 Research and Analysis Methods
1.4 Glossary of Terms Related to Neuromodulation Devices

2. An Introduction to Neuromodulation
2.1 Neuromodulation
2.2 Techniques Used in Neuromodulation
2.2.1 Electrical Stimulation Techniques Brain and Spinal Cord Therapies Cranial Nerve Stimulation Functional Electrical Stimulation
2.2.2 Pharmacological Therapy
2.3 Application of Neuromodulation
2.3.1 Pain Neuromodulation and Treatment of Pain
2.3.2 Depression Neuromodulation and Treatment of Depression
2.3.3 Epilepsy Neuromodulation and Treatment of Epilepsy
2.3.4 Urological Disorders: Overactive Bladder & Urinary Incontinence SNS and Treatment of Urinary Incontinence
2.3.5 Hearing Disorders: Profound Deafness
2.3.6 Cardiac Disorders: Arrhythmias & Angina Neuromodulation and Treatment of Cardiac Disorders
2.3.7 Parkinson’s Disease

3. The Global Neuromodulation Devices Market, 2010-2021
3.1 Scope and Limitations
3.2 Neuromodulation Devices is the Largest Segment in the Neurological Medical Devices Sector
3.3 Neuromodulation Devices Market in 2010
3.3.1 SCS Devices Dominate the Neuromodulation Devices Market in 2010
3.4 Medtronic is the Market Leader in the Neuromodulation Devices Market
3.5 Neuromodulation Devices in the Market
3.6 Leading Companies in the Neuromodulation Devices Market, 2010
3.6.1 Medtronic Medtronic Sales, 2010 Medtronic’s DBS and SCS Devices in the Market Medtronic’s Product Pipeline
3.6.2 St. Jude Medical (SJM) SJM Sales, 2010 SJM Neuromodulation Devices in the Market SJM Product Pipeline
3.6.3 Boston Scientific Boston Scientific Sales, 2010 Boston Scientific Neuromodulation Devices: Marketed and Pipeline
3.6.4 Cyberonics Cyberonics Sales, 2010 Cyberonics Neuromodulation Devices: Marketed and Pipeline
3.6.5 IntraPace
3.7 Neuromodulation Devices Market Forecast, 2011-2016
3.8 Neuromodulation Devices Market Forecast, 2016-2021
3.9 Changing Market Shares of the Leading Segments

4. Spinal Cord Stimulation Devices Market, 2010-2021
4.1 The US was the Largest Market for SCS Devices in 2010
4.2 Medtronic Dominated the US SCS Devices Market, Closely Followed by SJM and Boston Scientific
4.3 SCS Devices Market Forecast, 2011-2016
4.4 SCS Devices Market Forecast, 2016-2021
4.5 Competition in the SCS Market: Companies and Products
4.5.1 Medtronic
4.5.2 Boston Scientific
4.5.3 St. Jude Medical
4.5.4 Nevro

5. Deep Brain Stimulation Devices Market, 2010-2021
5.1 DBS Devices Market in 2010: Medtronic is the Only Company With an FDA Approved DBS Device
5.2 DBS Devices Market Forecast, 2011-2016
5.3 DBS Devices Market Forecast, 2016-2021
5.4 Competition in the DBS Devices Market: Companies and Products
5.4.1 Medtronic
5.4.2 St. Jude Medical

6. Vagus Nerve Stimulation Devices Market, 2010-2021
6.1 The US Contributed 81.3% of the VNS Market Sales in 2010
6.2 Majority of Sales of the VNS Devices Was for the Treatment of Refractory Epilepsy in 2010
6.3 Cyberonics Dominated the VNS Market in 2010
6.3.1 Cyberonics is Set to Lose its Monopoly in the VNS Devices Market
6.4 VNS Devices Market Forecast, 2011-2016
6.5 VNS Devices Market Forecast, 2016-2021
6.6 Competition in the VNS Devices Market: Companies and Products
6.6.1 Cyberonics
6.6.2 CerebralRx (a spin-off of BioControl Medical)
6.6.3 EnteroMedics

7. Neuromodulation Devices Pipeline
7.1 CVRx
7.2 Apnex Medical
7.3 ImThera Medical
7.4 NeuroPace
7.5 Intelect Medical (acquired by Boston Scientific Corporation)
7.6 EnteroMedics
7.7 MetaCure
7.8 Other Companies and Products

8. Leading National Markets, 2010-2021
8.1 Leading National Markets in 2010
8.2 The US Market Forecast, 2011-2021
8.3 The Japanese Market Forecast, 2011-2021
8.4 Leading European Markets Forecast, 2011-2021
8.4.1 The German Market
8.4.2 The French Market
8.4.3 The UK Market
8.4.4 The Italian Market
8.4.5 The Spanish Market
8.5 The Chinese Market Forecast, 2011-2021
8.6 The Indian Market Forecast, 2011-2021
8.7 Rest of the World (RoW)

9. SWOT Analysis of the Neuromodulation Device Industry, 2011-2021
9.1 Strengths
9.1.1 Neuromodulation Can be Seen as Safer Than Alternative Treatments
9.1.2 A Cost Effective Treatment Option
9.1.3 Neuromodulation Often Means Less Medication
9.2 Weaknesses
9.2.1 Neuromodulation Mechanisms Are Not Well Understood
9.2.2 A Small Number of Large Companies Dominate the Market
9.2.3 FDA Approvals
9.2.4 Failing Clinical Trials
9.3 Opportunities
9.3.1 Neuromodulation Market Set for Rapid Growth: Expanding Disease Indications
9.3.2 Increasing Prevalence of Neurological Diseases
9.3.3 The Potential of Personalised Medicine
9.4 Threats
9.4.1 Parkinson’s Disease May Soon be Treated with Stem Cells
9.4.2 SCS Faces Competition from Other Treatment Options

10. Expert Opinion
10.1 Interview with Michael Berman, Founder, Berman Medical
10.1.1 The Neuromodulation Market
10.1.2 Challenges Facing the Neuromodulation Market
10.1.3 Prospects for the Neuromodulation Market
10.2 Spokesperson from CVRx (Views Provided Anonymously)
10.2.1 Barostim neo: New Implantable Device for Hypertension
10.2.2 On the Development of Barostim neo
10.2.3 Competition for Barostim neo
10.2.4 On the Unmet Needs in the Market
10.3 Franck Fischer and Rebecca Kuhn, CEO and CFO, NeuroPace Inc
10.3.1 NeuroPace’s RNS Neuromodulation System for Epilepsy
10.3.2 The Neuromodulation and the Epilepsy Markets
10.3.3 Public Perception and Understanding of Neuromodulation
10.3.4 Small Companies Surviving in the Industry
10.3.5 Educating Physicians About Neuromodulation
10.3.6 Neuromodulation’s Role in Relation to Other Treatment Options
10.3.7 Recent Healthcare Reform in the US
10.3.8 Comparative Effectiveness Research

11. Conclusions
11.1 The Neuromodulation Devices Market is Dominated by Four Companies
11.2 The Neuromodulation Devices Market, 2011-2021
11.3 Neuromodulation Devices Will be Developed for New Indications: Driving Market Growth
11.4 Vast Opportunities for Growth in Emerging Markets
11.5 Introduction of Alternative Treatment Options Can Threaten Market Growth

Appendix A
Appendix B
Visiongain report evaluation form

About visiongain
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-2-business conferences, newsletters, management reports and e-zines focusing on the Energy, Telecoms, Pharmaceutical, Defence, Materials sectors.

Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port-of-call for the business professional, who needs independent, high quality, original material to rely and depend on.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44(0)207-336-6100


Biotechnology News

October 7 News

will not be displayed